nach oben

Neurological Sciences

Erschienen in:

01.05.2012 | CONTROVERSIES IN PROPHYLAXIS

Polytherapy for migraine prophylaxis

verfasst von: G. Casucci, V. Villani, D. Cologno, F. D’Onofrio

Erschienen in: Neurological Sciences | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a chronic neurological disorder with episodic manifestations, progressive in some individuals. Preventive treatment is recommended for patients with frequent or disabling attacks. A sizeable proportion of migraineurs in need of preventive treatment does not significantly benefit from monotherapy. This short review evaluates the role of pharmacological polytherapy in migraine prevention.

Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343–349PubMedCrossRef

Lipton RB, Pan J (2004) Is migraine a progressive brain disease? JAMA 291:493–494PubMedCrossRef

Lipton RB, Bigal ME (2005) Migraine: epidemiology, impact, and risk factors for progression. Headache 45(suppl 1):S3–S13PubMedCrossRef

Bigal ME, Lipton RB (2008) Concepts and mechanisms of migraine chronification. Headache 48:7–15PubMedCrossRef

Natoli J, Manak A, Dean B, Butler Q, Turkel C, Stovner L, Lipton R (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609PubMed

Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22:269–276PubMedCrossRef

Mathew NT (2011) Pathophysiology of chronic migraine and mode of action of preventive medications. Headache 51(S2):84–92PubMedCrossRef

Sher AI, Stewart WF, Ricci JA, Lipton RB (2003) Factors associated with the onset remission of chronic daily headache in a population-based study. Pain 6:81–88CrossRef

Rothrock JF (2008) Migraine “chronification”. Headache 48(1):181–182PubMedCrossRef

10.

Ramadan NM (2004) Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 8:91–95PubMedCrossRef

11.

Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054–1062PubMedCrossRef

12.

Evers S (2008) Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 9(15):2565–2573PubMedCrossRef

13.

Silberstein SD (2000) Evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 55:754PubMedCrossRef

14.

Capobianco DJ, Cheshire WP, Campbell JK (1996) An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc 71:1055–1066PubMedCrossRef

15.

Silberstein S (2009) Preventive migraine treatment. Neurol Clin 27:429–443PubMedCrossRef

16.

Bigal M, Krymchantowski AV, Lipton RB (2009) Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache 49(7):1028–1041PubMedCrossRef

17.

Prusinski A (1987) Monotherapy or politherapy in migraine. Neuroepidemiology 6:186–189PubMedCrossRef

18.

Kwan P, Brodie MJ (2000) Epilepsy after the first drug fails: substitution or add-on? Seizure 9:464–468PubMedCrossRef

19.

Peterlin BL, Calhoun AH, Siegel S, Mathew NT (2008) Rational combination therapy in refractory migraine. Headache 48:805–819PubMedCrossRef

20.

Rizzoli P, Loder EW (2011) Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanism. Headache 51(8):1336–1345PubMedCrossRef

21.

Rampello L, Alvano A, Chiechio S, Malaguarnera M, Raffaele R, Vecchio I, Nicoletti F (2004) Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology 50(4):322–328PubMedCrossRef

22.

Krymchantowsky AV, Silva MT, Barbosa JS, Alves LA (2002) Amitriptyline versus amitriptyline combined with fluoxetine in the preventive treatment of transformed migraine: a double blind study. Headache 42:510–514CrossRef

23.

Krymchantowsky AV, Hampshire F (2004) Polytherapy in migraine prevention. Clinical experience with the combination of a tricyclic antidepressant plus a calcium channel blocker. Headache 44:499–500

24.

Pascual J, Rivas MT, Leira R (2007) Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 115(2):81–83PubMedCrossRef

25.

Pascual J, Leira R, Lainez JM (2003) Combined therapy for migraine prevention? Clinical experience with a B-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23:961–962PubMedCrossRef

26.

Krymchantowski AV, Jevoux C, Bigal ME (2012) Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for non responders. J Headache Pain 13:53–59PubMedCrossRef

27.

Holroyd KA, Cottrell C, Donnell OF, Cordingley GE, Drew JB, Carlson BW, Himawan L (2010) Effect of preventive (β blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomized controlled trial. BMJ 341:c4871PubMedCrossRef

28.

Domingues R, Silva AL, Domingues SA, Aquino CC, Kuster GW (2009) A double-blind randomized controlled trial of low dose of propranolol, nortrypiline, and the combination of propranolol and nortryptiline for the preventive treatment of migraine. Arq Neuropsiquiatr 67(4):973–977PubMedCrossRef

29.

Luo N, Di W, Zhang A, Wang Y, Ding M, Qi W, Zhu Y, Massing MW, Fang Y (2012) A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 13:80–86PubMedCrossRef

30.

Gilron I, Bailey JM, Tu D, Holden RR, Jacson AC, Houlden RL (2009) Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet 374:1252–1261PubMedCrossRef

31.

Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319PubMedCrossRef

32.

Holland KD, Glauser TA (2007) Response to carbamazepine in children with newly diagnosed partial onset epilepsy. Neurology 69:596–599PubMedCrossRef

33.

Mohanraj R, Brodie MJ (2007) Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand 115:204–208PubMedCrossRef

34.

Bhise V (2009) When monotherapy for epilepsy fails. Neurol Rep 3(2)

35.

Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, Lipton RB (2007) Pharmacological approaches to managing migraine and associated comorbidities-clinical considerations for monotherapy versus polytherapy. Headache 47:585–599PubMedCrossRef

36.

Welch KM, D’Andrea G, Tepley N, Barkley G, Ramadan NM (1990) The concept of migraine as a state of central neuronal hyperexcitability. Headache 8:817

37.

D’Andrea G, Leon A (2010) Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurol Sci 31(suppl 1):S1–S7PubMedCrossRef

38.

Casucci G, Villani V, Frediani F (2008) Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci 29:S123–S126PubMedCrossRef

39.

Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652–661PubMedCrossRef

40.

Bogdanov VB, Multon S, Chauvel V, Bogdanova OV, Prodanov D, Makarchuk MY, Schoenen J (2011) Migraine preventive drugs differentially affect cortical spreading depression in rat. Neurobiol Dis 41:430–435PubMedCrossRef

41.

Nitsche MA, Lampe C, Antal A, Liebetanz D, Lang N, Tergau F, Paulus W (2006) Dopaminergic modulation of long lasting direct current-induced cortical excitability changes in the human motor cortex. Eur J Neurosci 23(6):1651–1657PubMedCrossRef

42.

Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P (2009) Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 89(2):176–192PubMedCrossRef

43.

Welch KMA, Ramadan MN (1995) Mitochondria, magnesium and migraine. J Neurol Sci 134(1–2):9–14PubMedCrossRef

44.

Barbiroli B, Montagna P, Cortelli P, Funicello R, Iotti S, Monari L, Pierangeli G, Zaniol P, Lugaresi E (1992) Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 42(6):1209–1214PubMedCrossRef

45.

Evans RW, Taylor FR (2006) Natural or alternative medications for migraine prevention. Headache 46:1012–1018PubMedCrossRef

46.

Frediani F, Villani V, Casucci G (2008) Peripheral mechanism of action of antimigraine prophylactic drugs. Neurol Sci 29:S127–S130PubMedCrossRef

Titel: Polytherapy for migraine prophylaxis
verfasst von: G. Casucci
V. Villani
D. Cologno
F. D’Onofrio
Publikationsdatum: 01.05.2012
Verlag: Springer Milan
Erschienen in: Neurological Sciences / Ausgabe Sonderheft 1/2012
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-012-1060-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2012

Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double-blind, randomized, multicenter, Italian study

Alcohol as a dietary trigger of primary headaches: what triggering site could be compatible?

Disability and mood state in patients with episodic and chronic migraine associated to medication overuse

Migraine and movement disorders

The real usefulness and indication for migraine diagnosis of neurophysiologic evaluation